Making Artificial Intelligence systems robustly perceive humans remains one of the most intricate challenges in computer ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

So, what is machine learning in the first place? And if the machines are so smart, why are they still so dumb? The point of ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Notably, Vertex Pharmaceuticals (NASDAQ: VRTX), which focuses on developing treatments for rare diseases, has significantly outpaced both its biotechnology peers and the S&P 500 since early 2022.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...

Houston-based Vertex Energy Inc. (OTCPK: VTNRQ) has released its restructuring plan after filing for bankruptcy protection with a move that will cancel and restructure all of its current stock.

Intracranial pressure may be just as critical of a factor in the progression of glaucoma as IOP, according to a speaker here ...

Google’s AI research lab DeepMind has achieved a new leap forward relative to other AI video generation models that are ...